Surv-Biopharma’s Oncolytic Virus Surv.m-CRA-1 Receives Orphan Drug Designation for Primary Malignant Bone Tumor
Key facts
- Surv-Biopharma’s Oncolytic Virus Surv.m-CRA-1 Receives Orphan Drug Designation for Primary Malignant Bone Tumor
- 鹿兒島大學發生技公司 Surv-Biopharma 開發之腫瘤溶解病毒「Surv.m-CRA-1」獲日本指定為原發性惡性骨腫瘤之「罕見疾病用再生醫療等產品」。
- Source: PR Times
- Date: May 12, 2026
Direct answer
鹿兒島大學發生技公司 Surv-Biopharma 開發之腫瘤溶解病毒「Surv.m-CRA-1」獲日本指定為原發性惡性骨腫瘤之「罕見疾病用再生醫療等產品」。
- Citation
- Surv-Biopharma’s Oncolytic Virus Surv.m-CRA-1 Receives Orphan Drug Designation for Primary Malignant Bone Tumor (May 12, 2026), PR Times
- Source
- PR Times
- Date
- May 12, 2026
鹿兒島大學發生技公司 Surv-Biopharma 開發之腫瘤溶解病毒「Surv.m-CRA-1」獲日本指定為原發性惡性骨腫瘤之「罕見疾病用再生醫療等產品」。
📋 Article Processing Timeline
- 📰 Published: May 12, 2026 at 04:32
- 🔍 Collected: May 11, 2026 at 20:02
- 🤖 AI Analyzed: May 16, 2026 at 02:54 (102h 52m after Collected)
Surv-Biopharma Inc., a biotech startup from Kagoshima University, announced that its oncolytic adenovirus "Surv.m-CRA-1" has been designated as an "Orphan Regenerative Medicine Product" by the Ministry of Health, Labour and Welfare of Japan. The therapy utilizes a survivin promoter to selectively destroy cancer cells while sparing healthy tissue. Currently in Phase III physician-led clinical trials, Surv.m-CRA-1 targets primary malignant bone tumors, a rare and difficult-to-treat cancer with high unmet medical needs. This designation provides incentives such as subsidies and priority review.
FAQ
Which specific biotech startup originating from Kagoshima University in Japan developed the oncolytic adenovirus named Surv.m-CRA-1?
Surv-Biopharma Inc. is the biotech startup from Kagoshima University that developed this oncolytic adenovirus therapy.
What official designation did the Ministry of Health, Labour and Welfare of Japan grant to Surv.m-CRA-1?
The Ministry of Health, Labour and Welfare of Japan designated Surv.m-CRA-1 as an Orphan Regenerative Medicine Product.
Which biological promoter does the oncolytic virus Surv.m-CRA-1 utilize to destroy cancer cells while sparing healthy tissue?
The Surv.m-CRA-1 therapy utilizes a survivin promoter to selectively destroy cancer cells while sparing healthy tissue.
What specific clinical trial phase is the oncolytic virus Surv.m-CRA-1 currently in for primary malignant bone tumors?
The oncolytic virus Surv.m-CRA-1 is currently in Phase III physician-led clinical trials for primary malignant bone tumors.
What benefits and incentives does Surv-Biopharma Inc. receive from the Orphan Regenerative Medicine Product designation in Japan?
This designation provides Surv-Biopharma Inc. with key incentives including financial subsidies and priority regulatory review.